Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis

Abstract

BackgroundPreventing exacerbations is an important goal of asthma treatment. Long-term treatment with azithromycin may help achieve this. Our aim was to conduct a systematic review and individual participant data (IPD) meta-analysis to examine the efficacy of azithromycin in reducing exacerbations in asthma, and in the subphenotypes of noneosinophilic asthma, eosinophilic asthma and severe asthma.MethodWe completed a systematic search of Embase, MEDLINE, PubMed, Cochrane Library, ClinicalTrials.gov and reference lists of previous systematic reviews in February 2019. We included parallel-group, double-blind, randomised controlled trials in adults comparing at least 8 weeks of azithromycin treatment with placebo, where the outcome of exacerbations was assessed over at least 6 months. Data were extracted from published sources, Cochrane Risk of Bias Tool was applied and IPD were sought from authors. Reviews were undertaken in duplicate. We conducted an IPD meta-analysis on the primary outcome of exacerbations and a random effects meta-analysis for secondary outcomes.ResultsThree studies were identified (n=604). In the IPD meta-analysis, treatment with azithromycin was associated with a reduced rate of exacerbations (oral corticosteroid course due to worsening asthma, antibiotic use for lower respiratory tract infection, hospitalisation and/or emergency department visits) in asthma as well as in the noneosinophilic, eosinophilic and severe asthma subgroups. Examining each exacerbation type separately, patients with eosinophilic asthma reported fewer oral corticosteroid courses, and patients with noneosinophilic and severe asthma reported fewer antibiotic courses. Azithromycin was well tolerated.DiscussionMaintenance use of azithromycin reduces exacerbations in patients with eosinophilic, noneosinophilic and severe asthma.

Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial

“…Azithromycin is a macrolide antibiotic, which has proven effective in reducing airway inflammation and consequent hospitalisation-requiring exacerbations of Chronic Obstructive Pulmonary Disease (COPD), asthma and bronchiectasis [ 5 – 7 ]. Recently, a strong association was found in critically ill patients with acute respiratory distress syndrome (ARDS) between treatment with azithromycin and improved survival [ 8 ] as summarised with greater power in systematic meta-analyses [ 9 , 10 ]. Further, hydroxychloroquine and azithromycin may act synergistically to prevent the coronavirus from binding to ganglioside receptors on human cells [ 11 ].…”

What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance

“…Severe asthma is a complex chronic disease, with a burdensome symptom profile and is associated with frequent asthma attacks, increased healthcare use, significant comorbidity and an increased mortality risk [1][2][3][4]. Recent advances have resulted in an increasing number of efficacious add-on treatment options for people with severe asthma [5][6][7][8][9][10]. Accordingly, patients and health professionals now have increased options for treatments, which also requires them to choose between different therapeutic options.…”

Chlamydia pneumoniae and chronic asthma: Updated systematic review and meta-analysis of population attributable risk

“…This systematic review/meta-analysis focused on chronic asthma, not asthma exacerbations, and was undertaken to update observational studies published since 2005, the date of the last review [8] and, for the first time, to estimate the population attributable risk (PAR) of Cp biomarkers in chronic asthma. Studies of short-term azalide/ketolide treatment for asthma exacerbations have been disappointing [47,48] whereas studies of long-term macrolide/azalide treatment for long-term management of chronic asthma have yielded clinically significant benefits [49], hence the focus on chronic asthma herein. Underlying mechanism(s) of action for macrolide benefits in chronic asthma are unknown and may include pathogen and hostdirected anti-inflammatory effects [50].…”